140 related articles for article (PubMed ID: 32925411)
21. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children.
Tanaka Y; Manabe A; Nakadate H; Kondoh K; Nakamura K; Koh K; Utano T; Kikuchi A; Komiyama T
Leuk Res; 2012 May; 36(5):560-4. PubMed ID: 22200619
[TBL] [Abstract][Full Text] [Related]
22. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia.
Innocenti F; Danesi R; Favre C; Nardi M; Menconi MC; Di Paolo A; Bocci G; Fogli S; Barbara C; Barachini S; Casazza G; Macchia P; Del Tacca M
Ther Drug Monit; 2000 Aug; 22(4):375-82. PubMed ID: 10942174
[TBL] [Abstract][Full Text] [Related]
23. Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia.
Conneely SE; Cooper SL; Rau RE
Front Oncol; 2020; 10():1129. PubMed ID: 32766146
[TBL] [Abstract][Full Text] [Related]
24. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
[TBL] [Abstract][Full Text] [Related]
25. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
[TBL] [Abstract][Full Text] [Related]
26. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Ogungbenro K; Aarons L;
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
[TBL] [Abstract][Full Text] [Related]
27. [Susceptibility to 6-mercaptopurine toxicity related with NUDT15 and ABCC4 variants in Japanese childhood acute lymphoblastic leukemia].
Tanaka Y
Rinsho Ketsueki; 2017; 58(8):950-956. PubMed ID: 28883280
[TBL] [Abstract][Full Text] [Related]
28. Inosine triphosphate pyrophosphohydrolase (ITPA) polymorphic sequence variants in Chinese ALL children and possible association with mercaptopurine related toxicity.
Ma X; Zheng J; Jin M; Li W; Gao C; Zhang D; Chen Y; Li X; Xie J
Int J Clin Exp Pathol; 2014; 7(7):4552-6. PubMed ID: 25120852
[TBL] [Abstract][Full Text] [Related]
29. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects.
Azimi F; Mortazavi Y; Alavi S; Khalili M; Ramazani A
Leuk Res; 2015 Oct; 39(10):1048-54. PubMed ID: 26242828
[TBL] [Abstract][Full Text] [Related]
30. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
[TBL] [Abstract][Full Text] [Related]
31. Skin Toxicity Due to Mercaptopurine in Maintenance Therapy Among Children With Acute Lymphoblastic Leukemia.
Higgerson K; Flatt T
J Pediatr Hematol Oncol; 2023 May; 45(4):e514-e517. PubMed ID: 37027323
[TBL] [Abstract][Full Text] [Related]
32. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
Giverhaug T; Loennechen T; Aarbakke J
Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
Hawwa AF; Millership JS; Collier PS; Vandenbroeck K; McCarthy A; Dempsey S; Cairns C; Collins J; Rodgers C; McElnay JC
Br J Clin Pharmacol; 2008 Oct; 66(4):517-28. PubMed ID: 18662289
[TBL] [Abstract][Full Text] [Related]
34. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
[TBL] [Abstract][Full Text] [Related]
35. Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.
Kouwenberg TW; van den Bosch BJC; Bierau J; Te Loo DMWM; Coenen MJH; Hagleitner MM
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e94-e97. PubMed ID: 31895215
[TBL] [Abstract][Full Text] [Related]
36. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
37. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
Schmiegelow K; Nielsen SN; Frandsen TL; Nersting J
J Pediatr Hematol Oncol; 2014 Oct; 36(7):503-17. PubMed ID: 24936744
[TBL] [Abstract][Full Text] [Related]
38. [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia].
Ma XL; Wang B; Guo HY; Zhang YH; Zhu GH; Duan YL; Yang J; Zhang DW; Jin L; Zhang R; Zhang L; Xie J; Wu MY
Zhonghua Er Ke Za Zhi; 2010 Apr; 48(4):289-92. PubMed ID: 20654019
[TBL] [Abstract][Full Text] [Related]
39. Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy.
Østergaard A; Bohnstedt C; Grell K; Degn M; Zeller B; Taskinen M; Hafsteinsdottir S; Björgvinsdóttir H; Heyman M; Hoogerbrugge P; Schmiegelow K;
Leukemia; 2021 Mar; 35(3):863-866. PubMed ID: 32623444
[No Abstract] [Full Text] [Related]
40. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Pui CH; Relling MV; Lascombes F; Harrison PL; Struxiano A; Mondesir JM; Ribeiro RC; Sandlund JT; Rivera GK; Evans WE; Mahmoud HH
Leukemia; 1997 Nov; 11(11):1813-6. PubMed ID: 9369411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
